Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion. clinical trials
3 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic confirmatory (Phase III)
RASBU-SEPSIS Study: Effects of rasburicase on renal function during sepsis – a randomized, placebo-controlled, double-blind trial
This study is looking at whether a medicine called rasburicase can help protect the kidneys of adults in intensive care with a serious infection called sepsis. We want to see if it can stop kidney problems from getting worse during the first week.
For: Patients hospitalised in intensive care · diagnosed with sepsis less than 48 hours ago · uric acid level ≥200µmol/LFrance - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination with Venetoclax in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)
This study is testing a new medicine, S227928, alone and with an existing drug, venetoclax (Venclyxto), for adults with certain types of blood cancers, like AML, MDS/AML, or CMML, that have returned or not responded to previous treatment.
For: "Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome (MDS)/AML · or Chronic Myelomonocytic Leukemia (CMML)"Finland · Germany · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients with CLL and Coexisting Medical Conditions
This study compares two treatments for chronic lymphocytic leukaemia (CLL) in patients who haven't had treatment before and have other health issues. It's looking at how well a new combination of medicines works against a standard treatment, aiming to find safer and more effective options.
For: Chronic Lymphocytic Leukemia (CLL)Bulgaria · Estonia · Romania